The Experts below are selected from a list of 13662 Experts worldwide ranked by ideXlab platform

Yongquan Zheng - One of the best experts on this subject based on the ideXlab platform.

Luca Rastrelli - One of the best experts on this subject based on the ideXlab platform.

  • determination of Carbendazim thiabendazole and thiophanate methyl in banana musa acuminata samples imported to italy
    Food Chemistry, 2004
    Co-Authors: Attilio Veneziano, Giovanni Vacca, Swizly Arana, Francesco De Simone, Luca Rastrelli
    Abstract:

    Abstract The occurrence of benzimidazole fungicides (benomyl and its metabolites Carbendazim, thiabendazole and thiophanate-methyl) in 50 banana samples imported to Italy from Ecuador, Panama and Costa Rica during 2002–2003 was investigated. In 11 samples, thiabendazole was found at concentrations ranging from 0.050 to 2.510 mg/kg. In five samples, Carbendazim was found at concentrations ranging from 0.140 to 1.100 mg/kg, whereas thiophanate-methyl was not detected in any sample. Analysis was carried out using HPLC-DAD and positive samples were confirmed by GC–MS. Recoveries of Carbendazim, thiabendazole and thiophanate-methyl at four fortification levels (0.5, 1.0, 2.5 and 4.0 mg/kg) were in the range 81–96% for Carbendazim and thiabendazole and 63.2–69.8% for thiophanate-methyl. Only two samples contained Carbendazim that exceeded the FAO/WHO Codex Alimentarius and the Italian Department of Health maximum residue limits.

Fengshou Dong - One of the best experts on this subject based on the ideXlab platform.

Yuhua Zhao - One of the best experts on this subject based on the ideXlab platform.

  • rhamnolipid aided biodegradation of Carbendazim by rhodococcus sp d 1 characteristics products and phytotoxicity
    Science of The Total Environment, 2017
    Co-Authors: Sheng Wang, Rexiding Abuduaini, Meinan Zhang, Yuhua Zhao
    Abstract:

    We successfully isolated Rhodococcus sp. D-1, an efficient Carbendazim-degrading bacterium that degraded 98.20% Carbendazim (200ppm) within 5days. Carbendazim was first processed into 2-aminobenzimidazole, converted to 2-hydroxybenzimidazole, and then further mineralized by subsequent processing. After genomic analysis, we hypothesized that D-1 may express a new kind of enzyme capable of hydrolyzing Carbendazim. In addition, the effect of the biodegradable biosurfactant rhamnolipid on the rate and extent of Carbendazim degradation was assessed in batch analyses. Notably, rhamnolipid affected Carbendazim biodegradation in a concentration-dependent manner with maximum biodegradation efficiency at 50ppm (at the critical micelle concentration, CMC) (97.33% degradation within 2days), whereas 150ppm (3 CMC) rhamnolipid inhibited initial degradation (0.01%, 99.26% degradation within 2 and 5days, respectively). Both Carbendazim emulsification and favorable changes in cell surface characteristics likely facilitated its direct uptake and subsequent biodegradation. Moreover, rhamnolipid facilitated Carbendazim detoxification. Collectively, these results offer preliminary guidelines for the biological removal of Carbendazim from the environment.

  • isolation and characterization of a new Carbendazim degrading ralstonia sp strain
    World Journal of Microbiology & Biotechnology, 2005
    Co-Authors: Guishan Zhang, Tianfan Cheng, Yuhua Zhao
    Abstract:

    A bacterial strain 1-1 capable of utilizing Carbendazim was isolated from Carbendazim-treated Qiyang red soils Hunan Province, China. It is gram-negative, rod-shaped, motile with peritrichous flagella, which formed round, smooth, convex and transparent colonies of about 1.1 mm diameter after 3 days of incubation on the isolation and purification medium using Carbendazim as the sole carbon and energy sources. The degradation ratios of Carbendazim by strain 1-1 were 19.16 and 95.96 in the Carbendazim (500 mg/l)-degrading medium and the Carbendazim (500 mg/l)-degrading medium supplemented with yeast extract (150 mg/l) within 24 days, respectively. Strain 1-1 was identified as Ralstonia sp. (β-Proteobacteria) based on the results of phenotypic features, G+C mol and phylogenetic analysis of 16S rDNA. Strain 1-1 could become a new bacterial resource for biodegrading Carbendazim and might play a bioremediation role for soils contaminated by Carbendazim.

Steven D Weitman - One of the best experts on this subject based on the ideXlab platform.

  • Carbendazim disposition cellular permeability metabolite identification and pharmacokinetic comparison with its nanoparticle
    Journal of Pharmaceutical Sciences, 2003
    Co-Authors: Hong Wong, Yao Wang, Mark Garza, Steven D Weitman
    Abstract:

    ABSTRACT The purpose of this study was to systematically evaluate the pharmacokinetic profiles of Carbendazim, a novel anticancer drug. Carbendazim reached the highest concentrations in stomach and small intestine by 1 h after oral administration (500 mg/kg) to tumor-bearing nude mice. Four hours later, Carbendazim in the large intestine reached maximum concentrations, probably because of pH-induced precipitation of the drug in the large intestine. The highest concentrations of Carbendazim in well-perfused tissues, solid tumor, and blood ranged from 63 to 164 μg/g by 4 h. The percentage of Carbendazim distributed to solid tumor by 4 h was higher than most well-perfused tissues. Carbendazim concentrations in blood were similar to, or somewhat lower than, those in tumor and other tissues. By 24 h post-dosing, Carbendazim concentrations in tissues and blood declined to almost basal levels. The total percentage of administered Carbendazim eliminated in urine was 25.7%, and in feces 16.6% within 24 h. Carbendazim exhibited fast permeation across Caco-2 and HT-29 carcinoma cell lines with corresponding permeability coefficients 7.74–8.06 × 10 −5 and 6.8–8.42 × 10 −5 (cm/s). The overall plasma protein binding of Carbendazim (0.2–125 μg/mL) assessed by ultrafiltration ranged from 60 to 74%. Comparative pharmacokinetics was conducted in rats by high-pressure liquid chromatography to evaluate the relative bioavailability of Carbendazim versus its nanoparticle formulation. Carbendazim and its nanoparticle reached T max at 2.01 and 1.57 h, respectively. The relative bioavailability of nanoparticle Carbendazim versus regular Carbendazim was 166%. High-pressure liquid chromatography analysis of the rat serum obtained at 20 h after oral dosing revealed a Carbendazim metabolite, which was identified by mass spectroscopy analysis as 2-aminobenzimidazole, a hydrolyzed product of Carbendazim. Incubation of Carbendazim with human and rat liver microsomes produced a metabolite identified by mass spectrometry as 5(6)- or 4(7)-hydroxyl Carbendazim. The comprehensive pharmacokinetic information is important to the current clinical investigation of Carbendazim.